Anika Therapeutics Projects 2026 Revenue Growth of 6%-10% and Improved EBITDA Margins
Anika Therapeutics (ANIK) reported a strong third quarter, highlighted by a 10% increase in revenue driven by growth across both commercial and OEM channels. CEO Stephen Griffin noted that the company's performance represents significant progress toward building a more profitable business model. Looking ahead to 2026, management has provided specific financial guidance, projecting annual revenue growth between 6% and 10%. Additionally, the company is targeting adjusted EBITDA margins in the range of 15% to 17%, signaling a strategic focus on operational efficiency and long-term profitability.
Tickers: $ANIK